| Field | Specification |
|---|---|
| Target | |
| Alternative names | Tumor necrosis factor ligand superfamily member 10; Apo-2 ligand; Apo-2L; TNF-related apoptosis-inducing ligand; Protein TRAIL; CD253; TNFSF10; APO2L, TRAIL; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E. coli-derived human TRAIL recombinant protein (Position: N40-A272). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets tumor necrosis factor ligand superfamily member 10 (gene TNFSF10) in human, mouse and rat samples and is validated for IHC and Western blot. The predicted molecular weight is 32.5 kDa, and the supplier reports an observed band at about 35 kDa.
TRAIL (TNFSF10, Apo2L) is a TNF family cytokine that induces apoptosis by engaging the death receptors DR4 (TNFRSF10A) and DR5 (TNFRSF10B). Its activity is tuned by decoy receptors, including TNFRSF10C, TNFRSF10D and osteoprotegerin, which bind TRAIL without triggering cell death. TRAIL is studied in cancer biology, immune surveillance and apoptosis research.
| Target | Tumor necrosis factor ligand superfamily member 10 (gene TNFSF10; UniProt P50591, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.05 mg NaN3 |
| Calculated MW | 32.5 kDa |
| Observed MW | 35 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 0.5–1 µg/mL (Human, Mouse, Rat) |
Samples with a confirmed band (WB): human HL-60 cells, human THP-1 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 50 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:10000, ECL detection.
Samples with confirmed staining (IHC): human tonsil tissue, mouse spleen tissue, rat liver tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in citrate buffer (pH 6).
Immunogen
Recombinant human TRAIL fragment (Asn40–Ala272), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt describes tumor necrosis factor ligand superfamily member 10 as secreted and also located in the cell membrane. Tissue expression noted by UniProt (human): Widespread. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Tianshan She et al. (2023) Snoopligase-catalyzed molecular glue enables efficient generation of hyperoligomerized TRAIL variant with enhanced antitumor effect. Journal of Controlled Release. 10.1016/j.jconrel.2023.07.042
Xue Jin et al. (2014) Multifunctional cationic polymer decorated and drug intercalated layered silicate (NLS) for early gastric cancer prevention. Biomaterials. 10.1016/j.biomaterials.2013.12.040
Li Shaodong et al. (2025) PARP1 contributes to intimal hyperplasia by regulating METTL3-mediated m6A methylation of TRAIL. Cell Biology and Toxicology. 10.1007/s10565-025-10076-w
Huang Can et al. (2017) AAV-iRFP labelling of human mesenchymal stem cells for near-infrared fluorescence imaging. Bioscience Reports. 10.1042/BSR20160556
Guangxiang Zang et al. (2009) Adenoviral mediated transduction of adenoid cystic carcinoma by human TRAIL gene driven with hTERT tumor specific promoter induces apoptosis. Cancer Biology & Therapy. 10.4161/cbt.8.10.8117
Xiaojie Sun et al. (2018) Tumor necrosis factor-related apoptosis inducing ligand overexpression and Taxol treatment suppresses the growth of cervical cancer cells in vitro and in vivo. Oncology Letters. 10.3892/ol.2018.8071
